Analysts Set Expectations for Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.87) EPS and FY2028 earnings at ($2.24) EPS.

Nuvectis Pharma Trading Down 2.2 %

Shares of NASDAQ:NVCT opened at $6.71 on Friday. The stock’s fifty day simple moving average is $6.22 and its two-hundred day simple moving average is $6.41. The stock has a market cap of $129.64 million, a PE ratio of -5.78 and a beta of 0.22. Nuvectis Pharma has a 1-year low of $4.44 and a 1-year high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, March 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08).

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC bought a new position in shares of Nuvectis Pharma in the 4th quarter worth approximately $34,000. Nations Financial Group Inc. IA ADV purchased a new position in Nuvectis Pharma in the 3rd quarter worth approximately $63,000. Baxter Bros Inc. increased its holdings in Nuvectis Pharma by 20.0% in the 4th quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock worth $81,000 after buying an additional 2,500 shares in the last quarter. Squarepoint Ops LLC bought a new position in Nuvectis Pharma during the fourth quarter valued at approximately $103,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Nuvectis Pharma in the 4th quarter worth $135,000. 96.77% of the stock is owned by institutional investors.

Insider Buying and Selling at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $4.70 per share, for a total transaction of $79,900.00. Following the completion of the transaction, the insider now directly owns 2,612,000 shares in the company, valued at $12,276,400. This trade represents a 0.66 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have bought a total of 261,500 shares of company stock worth $1,300,825 over the last ninety days. 35.78% of the stock is currently owned by company insiders.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.